Previous 10 | Next 10 |
Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), a pharmaceutical company focused on the discovery, development and commercialization of first-in-class ophthalmic therapies, today announced that it will present second quarter 2022 financial results after the market closes Thursday, August 4,...
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a pharmaceutical company focused on the discovery, development, and commercialization of first-in-class ophthalmic therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases today announced th...
AERI For Seeking Alpha's full earnings season calendar, click here. For further details see: Notable earnings after Friday's close
Aerie Pharmaceuticals (NASDAQ:AERI) is scheduled to announce Q2 earnings results on Friday, June 10th, after market close. The consensus EPS Estimate is -$0.55 (+33.7% Y/Y) and the consensus Revenue Estimate is $32.53M (+19.6% Y/Y). Over the last 2 years, AERI has beaten EPS estimates 25% of ...
Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), a pharmaceutical company focused on the discovery, development and commercialization of first-in-class ophthalmic therapies, today announced that Raj Kannan, Chief Executive Officer, along with Peter Lang, Chief Financial Officer, and Dr. Gary...
Aerie Pharmaceuticals (NASDAQ:AERI) said the first person was dosed in a phase 3 trial of AR-15512 ophthalmic solution to treat the signs and symptoms of dry eye disease. The company added that the phase 3 study, dubbed COMET-2, is the first of three trials in the phase 3 registrational ...
AR-15512 is a differentiated, novel, first-in-class product candidate for the treatment of the signs and symptoms of Dry Eye Disease COMET-2 is the first of three studies in the AR-15512 Phase 3 Program Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), a pharmaceutical com...
Aerie Pharmaceuticals, Inc. (AERI) Q1 2022 Earnings Conference Call May 5, 2022 5:00 PM ET Company Participants Hans Vitzthum – LifeSci Partners Raj Kannan – Chief Executive Officer Gary Sternberg – Chief Medical Officer Peter Lang – Chief Financial Officer Confere...
Aerie Pharmaceuticals press release (NASDAQ:AERI): Q1 Non-GAAP EPS of -$0.66 misses by $0.01. Revenue of $29.83M (+29.9% Y/Y) misses by $0.07M. Reaffirms 2022 Glaucoma Franchise Guidance of $130 Million to $140 Million. Cash, cash equivalents and total investments were $199.2 million as ...
First Quarter Glaucoma Franchise Net Revenues of $29.8 Million, up 30% over First Quarter 2021 Management Reaffirms 2022 Glaucoma Franchise Guidance of $130 Million to $140 Million First Phase 3 Registrational Trial for AR-15512 On-Track for Enrollment Second Quarter o...
News, Short Squeeze, Breakout and More Instantly...
Aerie Pharmaceuticals Inc. Company Name:
AERI Stock Symbol:
NASDAQ Market:
Aerie Pharmaceuticals Inc. Website:
Leveraging Alcon’s robust commercial capabilities and resources to drive further growth and access to Rocklatan and Rhopressa Acquisition adds pharmaceutical research and development capabilities and further expertise for future product pipeline Expands Al...
Third Quarter Glaucoma Franchise Net Revenues of $36.1 Million, up 23% over Third Quarter 2021 Previously Announced Agreement to be Acquired by Alcon; Transaction Expected to Close in the Fourth Quarter of 2022 Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), a pharmaceut...
NEW YORK, NY / ACCESSWIRE / October 30, 2022 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Altra Industrial Motion Corp. (NA...